premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We once again reiterate this low cost oil and gas producer in the Montney and Duvernay shale regions as a TOP PICK. Recently reported earnings show free cash flow exceeding the last three years combined, allowing for debt to be retired and shares bought back.  The company's strategy is to payout 75% of FCF to shareholders and use the balance to reduce debt.  It pays a fine dividend, backed by a payout ratio under 15% of cash flow.  We continue to recommend a stop-loss at $9.25, looking to achieve $15.00 -- upside potential over 36%. Yield 5.3%

(Analysts’ price target is $14.88)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We reiterate this operator of 31,000 single family homes and multi-family rental apartments in 21 markets in US and Canada as a TOP PICK.  It trades under book value, while supporting a ROE of 28%.  Cash reserves are prudently being used to continue aggressively retiring debt. We recommend trailing up the stop-loss (from $8.50) to $10.00, looking to achieve 15.00 -- upside potential over 20%. Yield 1.9%

(Analysts’ price target is $15.09)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We again reiterate ET, one of the largest midstream energy companies in the world and who exports 20% of global natural gas liquids, as a TOP PICK.  Earnings tomorrow should confirm recent acquisition assets and existing investment in their coastal terminals are buzzing with activity.  It trades at 1.2x book value and 10x earnings.  We like how they have aggressively been retiring debt.  The dividend yield is excellent and supported by a payout ratio under 60% of cash flow. We recommend trailing up the stop-loss (from $10.75) to $11.50, looking to achieve $16.50 -- upside potential over 24%. Yield 6.7%

(Analysts’ price target is $16.50)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 19/23, Up 20.4%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with ABNB is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $80) to $90.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 29/22, Up 17.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with CAR.UN is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $39) to $44.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 29/22, Up 17.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with FISV is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $93) to $100.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jun 14/22, Up 16.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with FCX is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $33) to $37.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jun 21/22, Up 15.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with EBAY is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $35) to $43.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 15/22, Up 14.4%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with LNR is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $54.50) to $62.00.

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 13/22, Up 14.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with BEI.UN is progressing well.  To remain disciplined, we now recommend trailing up the stop (from $44.70) to $50.00.

COMMENT

Today's inflation number of 6.4% YOY was a little hotter than expected, but lower than last June's 9.1% in the US.  Hotter than expected, but inflation is coming down in commodities, housing and used cars. This will lead to central banks to pause rate hikes and pivot later this year. Since 1950, when inflation is lower after a high year, the S&P has returned 12.6% on average and 75% of the time we are positive on the year. 70% of the S&P stocks are trading above their 200-day moving averages, so this looks very promising. Since 1950, back to back years on the S&P have happened only 3 times (mid-70s and 2002). He likes energy especially, financials and health care. Also, discretionary as inflation cools and China reopens.

BUY

Good cash flow and pays a 3.7x dividend. Cheap at 12x PE. Good cardio drug in the pipeline, looking promising. Shares are down lately because of a general rotation and society is getting indifferent to Covid and vaccines. Management sees 7-9% revenue growth outside Covid vaccines. Strong balance sheet. Offers defence and offence.

BUY

Pays a 4.5% dividend that will increase. Global demand for oil continues to outstrip supply, which is minimal these days. Are disciplined and instead enhancing share buybacks and dividends. China reopening is a catalyst.

DON'T BUY

Pays a 3.9% dividend, paying 14x forward earnings, but the EPS growth rate is likely under 5% annual forward. Problem is their big drug Humira comprises 43% of overall sales, but this patent expires this year--that's a problem. Abbvie does have a good pipeline though. Prefers Pfizer, Merck, etc.

BUY
Canadian dividend ETF

Also likes VDY-T and XEI-T, which he owns. Both include financials and pipelines.